StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) stock

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.86−0.10 (-2.53%)

Close on Nov 17, 2026Market cap $188.72MP/E –Yield –

Artiva Biotherapeutics cash

Cash and short-term investments held at the end of each period.

Artiva Biotherapeutics's cash was $349.40M at Jun 30, 2026. For fiscal 2025 it was $108.00M, down 41.7% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$108.00M-41.7%
FY2024Dec 31, 2024$185.40M+140.1%
FY2023Dec 31, 2023$77.23M-24.9%
FY2022Dec 31, 2022$102.78M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$349.40M+145.4%
Q1 FY2026Mar 31, 2026$86.80M-47.7%
Q4 FY2025Dec 31, 2025$108.00M-41.7%
Q3 FY2025Sep 30, 2025$123.00M-38.4%
Q2 FY2025Jun 30, 2025$142.40M+205.9%
Q1 FY2025Mar 31, 2025$166.00M+244.4%
Q4 FY2024Dec 31, 2024$185.40M+140.1%
Q3 FY2024Sep 30, 2024$199.60M+203.0%
Q2 FY2024Jun 30, 2024$46.56M-13.3%
Q1 FY2024Mar 31, 2024$48.20M-53.1%
Q4 FY2023Dec 31, 2023$77.23M–
Q3 FY2023Sep 30, 2023$65.89M–
Q2 FY2023Jun 30, 2023$53.70M–
Q4 FY2022Dec 31, 2022$102.78M–

More Artiva Biotherapeutics figures

See a number that looks wrong?